Asthma

Description
Xolair® is a monoclonal antibody that attaches to immunoglobulin E (IgE), an antibody involved in the body’s response to allergens, and prevents it from binding to other cells in the body’s immune system. Blocking IgE prevents the release of substances that are involved in the inflammatory processes associated with asthma. It is FDA approved for the treatment of moderate to severe persistent asthma in patients 6 years of age or older who have a positive skin test to a perennial aeroallergen or whose symptoms are not well controlled with inhaled corticosteroids.

Dosing and Administration
Xolair® is a subcutaneous injection that must be administered by a healthcare professional. The recommended dose for Xolair® is 75 to 375 mg every two or four weeks.

Common Side Effects
The most common side effects of Xolair® include arthralgia, general pain, leg pain, fatigue, dizziness, fracture, arm pain, pruritus, dermatitis, and earache.

Description
CINQAIR® is a human monoclonal antibody that blocks the activity of interleukin-5 associated with the production and survival of eosinophils, a type of cell that is involved in the inflammatory processes associated with asthma. It is FDA approved for the add-on maintenance treatment of patients with severe asthma aged 18 years and older and an eosinophilic phenotype.

Dosing and Administration
CINQAIR® is an intravenous infusion that must be administered by a healthcare professional. The recommended dose for CINQAIR® is 3 mg/kg every four weeks.

Common Side Effects
The most common side effect of CINQAIR® is oropharyngeal pain.

Description
Fasenra™ is a human monoclonal antibody that blocks the activity of interleukin-5 associated with the production and survival of eosinophils, a type of cell that is involved in the inflammatory processes associated with asthma. It is FDA approved for the add-on maintenance treatment of patients with severe asthma aged 12 years and older with an eosinophilic phenotype.

Dosing and Administration
Fasenra™ is a subcutaneous injection that must be administered by a healthcare professional. The recommended dose for Fasenra™ is 30 mg once every four weeks for the first three doses, then every eight weeks.

Common Side Effects
The most common side effects of Fasenra™ include headache and pharyngitis.

Description
Nucala® is a human monoclonal antibody that blocks the activity of interleukin-5 associated with the production and survival of eosinophils, a type of cell that is involved in the inflammatory processes associated with asthma. It is FDA approved for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, with an eosinophilic phenotype.

Dosing and Administration
Nucala® is a subcutaneous injection that must be administered by a healthcare professional. The recommended dose of Nucala® is 100 mg every four weeks.

Common Side Effects
The most common side effects of Nucala® include headache, injection site reaction, back pain, and fatigue.

Description
Dupixent® is a human monoclonal antibody that blocks the activity of interleukin-4 and prevents the release of substances that are involved in the inflammatory processes associated with asthma. It is FDA approved for the add-on maintenance treatment of patients with moderate to severe asthma aged 12 years and older with an eosinophilic phenotype, or with oral corticosteroid dependent asthma.

Dosing and Administration
Dupixent® is a subcutaneous injection that must be administered by a healthcare professional. The recommended dose for Dupixent® is 400 mg for one dose followed by 200 mg every other week, or 600 mg for one dose followed by 300 mg every other week.

Common Side Effects
The most common side effects of Dupixent® include injection site reactions, oropharyngeal pain, and eosinophilia.